Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 3/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845506 | 0.91 | S1PR2 (0.34) | S1PR2PRKAA2BRD4CREBBPMAPK14 | |
| SCHEMBL22845431 | 0.90 | GRM5 (0.38) | PRKAA2GRM1SMN1; SMN2 | |
| SCHEMBL22845442 | 0.88 | GRM5 (0.34) | S1PR2PRKAA2GRM1MAPK14ALDH1A1 | |
| SCHEMBL22845278 | 0.86 | GRM5 (0.32) | USP7GRM1MAPK14 | |
| SCHEMBL24173941 | 0.85 | GRM1 (0.39) | USP7GRM1SMN1; SMN2 | |
| SCHEMBL22845357 | 0.84 | PRLHR (0.35) | ALDH1A1 | |
| SCHEMBL22845323 | 0.84 | MTHFD2 (0.34) | BRD4CREBBPMAPK14KDRALDH1A1 | |
| SCHEMBL22845502 | 0.82 | GRM1 (0.34) | USP7GRM1 | |
| SCHEMBL22845531 | 0.82 | MAPK14 (0.35) | MAPK14 | |
| SCHEMBL22845344 | 0.81 | USP7 (0.32) | USP7GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | S1PR2 2103/4885TNF 3737/4885PRKAA2 2338/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | S1PR2 2103/4885TNF 3737/4885PRKAA2 2338/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | S1PR2 2103/4885TNF 3737/4885PRKAA2 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.